Loading data for HROW — first visit, this takes a few seconds.
Harrow, Inc. (HROW)
NasdaqGM: HROW
· Real-Time Price · USD
36.97
+0.06 (0.16%)
At close: Sep 02, 2026, 8:00 PM
38.77
-0.72%
Pre-market: 4:01 AM
The price, the headline numbers and the latest news, in one place.
Harrow, Inc. (HROW) Stock Price, Analysis & Data
No data available
| Bid | 28.48 |
| Market Cap | 1.46B |
| Revenue (ttm) | 276M |
| Net Income (ttm) | -37.2M |
| 0.25 | |
| -1.05 | |
| n/a | |
| 14.27 | |
| P/B (ttm) | 96.18 |
| P/S (ttm) | 5.31 |
| Earnings Date | Nov 9, 2026 |
| Ask | 51.2 |
| Volume | 359,607 |
| Avg. Volume (20D) | 656,133 |
| Open | 36.79 |
| Previous Close | 36.91 |
| Day's Range | 36.66 - 37.49 |
| 52-Week Range | 28.54 - 54.85 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About HROW
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as B...
Sector Healthcare
IPO Date Sep 28, 2007
Employees 373
Stock Exchange NasdaqGM
Ticker Symbol HROW
Website https://www.harrow.com
Financial Performance
In 2025, Harrow's revenue was 272.3M, an increase of 36.41% compared to the previous year's 199.61M. Earnings were -5.14M, a decrease of -70.6%.
Financial StatementsEarnings Surprise
Harrow has released their quarterly earnings on Aug 10, 2026:
- Revenue of $44.2M misses estimates by $0, with -7.59% YoY decline.
- EPS of -0.46 misses estimates by -0.22, with -291.67% YoY decline.
Harrow, Inc. is scheduled to release its earnings on Nov 9, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2